Effect of atorvastatin on lipogenic, inflammatory and thrombogenic markers in women with the metabolic syndrome

Gladys P. Velarde, Naila Choudhary, Katia Bravo-Jaimes, Carmen Smotherman, Saadia Sherazi, Dale F. Kraemer

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Background and aim: Specific drug therapy to target the underlying proinflammatory and prothrombotic state in patients with metabolic syndrome (MS) is lacking. We sought to study the effect of high-intensity atorvastatin on markers of lipogenesis, inflammation and thrombogenesis, in women with MS in the absence of cardiovascular disease or diabetes. Methods and results: This randomized double-blinded controlled trial included 88 women with MS (according to National Cholesterol Education Panel Adult Treatment Panel III criteria) and low atherosclerotic cardiovascular risk. Participants were randomized to receive atorvastatin 80 mg or matching placebo. Thrombogenic, lipogenic and inflammatory markers were collected at the time of enrollment, after a 6-week dietary run-in phase (time of randomization), and at 6- and 12-weeks after randomization. At 6 weeks post-randomization, there was significant reduction in total cholesterol, low density lipoprotein cholesterol, triglycerides, apolipoprotein-B (Apo-B) and Apo-B/Apo-A1 ratio in the atorvastatin arm compared to placebo. This difference persisted at 12-weeks post randomization. There was no significant difference in fasting blood glucose, high-density lipoprotein cholesterol, high sensitivity C-reactive protein, serum leptin, Apo-A1, intercellular adhesion molecule 1 and platelet activity. A significant increase in vascular adhesion molecule 1 at 6 and 12 weeks was seen within the atorvastatin arm. No difference was observed in blood pressure and waist circumference. Conclusions: In conclusion, high-intensity atorvastatin has an early and significant impact on lipoproteins and apolipoproteins but did not lower inflammatory, thrombogenic or biomarkers of platelet activity and aggregation in women with MS. The use of statins for primary prevention in these patients should be further explored.

Original languageEnglish (US)
Pages (from-to)634-640
Number of pages7
JournalNutrition, Metabolism and Cardiovascular Diseases
Issue number2
StatePublished - Feb 8 2021


  • Biomarkers
  • Metabolic syndrome
  • Randomized trial
  • Statins

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Endocrinology, Diabetes and Metabolism
  • Nutrition and Dietetics
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Effect of atorvastatin on lipogenic, inflammatory and thrombogenic markers in women with the metabolic syndrome'. Together they form a unique fingerprint.

Cite this